HFS
LCTX icon

Hantz Financial Services’s Lineage Cell Therapeutics LCTX Stock Holding History

Hantz Financial Services’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$0 Hold
29
– – ﹤0.01% 2546
2025
Q4 		$0 Hold
29
– – ﹤0.01% 2484
2025
Q3 		$0 Hold
29
– – ﹤0.01% 2403
2025
Q2 		$0 Hold
29
– – ﹤0.01% 2251
2025
Q1 		$0 Hold
29
– – ﹤0.01% 1855
2024
Q4 		$0 Hold
29
– – ﹤0.01% 1162
2024
Q3 		$0 Hold
29
– – ﹤0.01% 1139
2024
Q2 		$0 Hold
29
– – ﹤0.01% 1182
2024
Q1 		$0 Hold
29
– – ﹤0.01% 1255
2023
Q4 		$0 Hold
29
– – ﹤0.01% 1185
2023
Q3 		$0 Hold
29
– – ﹤0.01% 1155
2023
Q2 		$0 Hold
29
– – ﹤0.01% 1135
2023
Q1 		$0 Hold
29
– – ﹤0.01% 1164
2022
Q4 		$0 Hold
29
– – ﹤0.01% 1123
2022
Q3 		$0 Hold
29
– – ﹤0.01% 1112
2022
Q2 		$0 Hold
29
– – ﹤0.01% 1080
2022
Q1 		$0 Buy
+29
New +$45 ﹤0.01% 1084

Other funds holding LCTX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
RA
Raffles Associates New York $115M AUM 35.69% 1-Year Est. Return
Fifth Third Bancorp
Fifth Third Bancorp Cincinnati, Ohio $54.7B AUM 26.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Hantz Financial Services's LCTX Position: Q1 2026 in Review

Hantz Financial Services held its Lineage Cell Therapeutics (LCTX) position steady in Q1 2026 at 29 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #2546.

Hantz Financial Services first reported a position in LCTX in Q1 2022 and has held it in 17 quarters since. 130 funds tracked by Wall St. Rank hold LCTX as of Q1 2026.

  • Hantz Financial Services held 29 shares of Lineage Cell Therapeutics worth $0 as of Q1 2026.
  • Hantz Financial Services left its Lineage Cell Therapeutics share count unchanged in Q1 2026.
  • Lineage Cell Therapeutics made up ﹤0.01% of Hantz Financial Services's portfolio in Q1 2026, its #2546 holding.
  • Hantz Financial Services first reported a position in Lineage Cell Therapeutics in Q1 2022 and has held it in 17 quarters since.
  • 130 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q1 2026.

Based on Hantz Financial Services's 13F filing for Q1 2026, filed 1 May 2026.